AGIOS PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
AGIOS PHARMACEUTICALS, INC. (AGIO) had Available-for-sale Securities, Amortized Cost Basis of $509.51 million as of 2017-09-30, per its 10-Q filed 2017-11-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2017-11-01
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $509.51M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $577.87M.
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $413.12M.
- 2015-09-30: Available-for-sale Securities, Amortized Cost Basis $327.71M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-09-30 | $509.51M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $577.87M 10-Q · filed 2017-08-08 |
| 2016-12-31 | $413.12M 10-Q · filed 2017-11-01 |
| 2015-09-30 | $327.71M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $361.28M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $404.52M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $453.47M 10-Q · filed 2015-11-06 |
| 2014-09-30 | $167.79M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $152.85M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $134.40M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $122.32M 10-K · filed 2015-02-24 |
| 2013-09-30 | $102.33M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $21.80M 10-Q · filed 2013-09-05 |
| 2012-12-31 | $36.68M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |